This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit December 17, 2014


 

Advertisement

Genomic health test could reduce overtreatment of breast cancer
Forbes
Recently, the San Antonio Breast Cancer Symposium featured new evidence for a tool that might inform treatment decisions in women with low-grade breast tumors. Since the 1980s, diagnoses of DCIS (ductal carcinoma in situ) have risen dramatically due to enhanced screening. Questions about this condition — whether it's likely to cause harm and how to manage it — are central to debate about mammography, the concept of overdiagnosis, and overtreatment.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  


Advertisement


Study shows numeracy linked to bowel cancer screening
News-Medical.Net
People who have problems with numbers may be more likely to feel negative about bowel cancer screening, including fearing an abnormal result, while some think the test is disgusting or embarrassing, according to a Cancer Research UK-supported study published recently in the Journal of Health Psychology. The researchers sent information about bowel cancer screening to patients aged from 45 to 59 along with a questionnaire that assessed their numerical skills and attitudes to the screening test, which looks for blood in stool samples.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
SPONSORED CONTENT


UnitedHealthcare, MD Anderson deal may spur more bundled payments in cancer
Modern Healthcare
Two major players in the private sector have launched a fixed-payment structure for cancer care that could serve as a harbinger of similar arrangements as the appetite for such payment reforms continues to grow across the industry.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Registration now open for Accreditation 101: Learning the Basics of CoC Accreditation and Standards
The Commission on Cancer (CoC), a Quality Program of the American College of Surgeons, encourages you to attend Accreditation 101: Learning the Basics of CoC Accreditation and Standards in Chicago on February 27, 2015. This program provides practical information on how to achieve compliance and discusses your role as a member of a patient-centered, multidisciplinary cancer care team. This is the only education program that is developed and taught by CoC surveyors and staff. Learn how to turn theory into reality and see how the CoC standards can be used as a guide for the development of a high-quality program that treats patients with cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  Oncology Data Consulting Services
Successfully prepare for ACS CoC accreditation with an ACS CoC trained consultant or conduct an operations review for planning and assessment of your oncology registry and program.

Learn more about our Oncology Data Services consulting options.

Download our white paper: “Making Sense of the Rapid Quality Reporting System.”
 


Hormone-unrelated breast cancer death rate lowered by reducing dietary fat
Medical News Today
Reducing dietary fat intake for at least five years after diagnosis could help improve survival rates for early-stage breast cancer patients with hormone-unrelated breast cancer, according to a new study. The findings of the study were presented at the 2014 San Antonio Breast Cancer Symposium, a five-day conference aiming to provide state-of-the-art information on breast cancer research to an audience of researchers and physicians from more than 90 countries.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Miss an issue of The CoC Brief? Click here to visit The CoC Brief archive page.


Managing obesity should be part of cancer care
Oncology Nurse Advisor
Obesity is at an epidemic level in the United States and globally. More than two-thirds of American adults are overweight or obese. Obesity contributes to avoidable and premature deaths from the top two killers: cardiovascular disease and cancer. People who are overweight or obese have a higher risk of other serious health conditions, including type 2 diabetes and high blood pressure.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Ottawa cancer researcher says new approach to cancer could bring cure
CTV
VideoBrief There are exciting times for cancer researchers in Canada, particularly a leading-edge team in Ottawa. They are forming a nationwide partnership, and they are talking about a cure. Ottawa's own Dr. John Bell takes the lead on this research. With $60 million dollars in funding, they are setting out to find ways that a patient's own body can help cure his or her cancer. For decades, the treatment protocol for cancer has been powerful chemotherapy drugs that are sometimes as harsh as the diagnosis itself and radiation that can leave burns and scars.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Molecular link discovered between prostate and breast cancer suggests new treatment approach for men's tumor
Weill Cornell Medical College
Prostate cancer can be driven by the same estrogen receptor responsible for the most common form of breast cancer, Weill Cornell Medical College researchers report. Their findings suggest why the most aggressive forms of prostate cancer do not respond to traditional therapy. The study also opens up potential for new prognostic biomarkers and treatments, researchers say.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Herceptin for HER2-positive breast cancer improves long-term survival
Medical News Today
A study that analyzed the long-term safety and effectiveness of trastuzumab — more commonly known as Herceptin — found it significantly improves long-term survival of patients with HER2-positive breast cancer when combined with chemotherapy. The study, published in the Journal of Clinical Oncology, analyzed data from two independent trials designed to examine overall survival of patients with early-stage HER2-positive breast cancer who received chemotherapy with and without Herceptin.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Preclinical studies confirm TRXE-009 as new potential treatment for melanoma
News-Medical.Net
Novogen Limited, an Australian/US biotechnology company, recently announced that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in preclinical studies also to be highly active against melanoma. The company believes this is an important breakthrough discovery for two reasons. The first is that it confirms that TRXE-009 is an important new potential treatment for melanoma, including for the treatment of secondary brain cancers due to melanoma for which there currently are no effective therapies. The second is that it offers evidence for the first time of a hypothesized link between brain cancer and melanoma.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    How hospitals can go green, save green with food waste disposal (FierceHealthcare)
50 of the most powerful people in healthcare 2015 (Becker's Hospital Review)
10 smartest things people in healthcare do (Becker's Hospital Review)
4 environmental health lessons learned from the Bhopal disaster (The Huffington Post)
CleanMed — leading by example (Practice Greenhealth)

Don't be left behind. Click here to see what else you missed.
 
Advertisement



The CoC Brief

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Ashley Whipple, Senior Content Editor, 469.420.2642
Contribute news

Disclaimer: The CoC Brief is a digest of the most important news selected for the American College of Surgeons Commission on Cancer from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Commission on Cancer does not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons and the Commission on Cancer.


Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of The CoC Brief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Dec. 10, 2014
Dec. 3, 2014
Nov. 26, 2014
Nov. 12, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063